SM
ANTH

Sabby Management’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Sabby Management’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-52,046
Closed -$89.6K – 219
2017
Q3 		$75K Sell
52,046
-540,626
-91% -$768K ﹤0.01% 147
2017
Q2 		$960K Buy
592,672
+372,960
+170% +$836K 0.06% 104
2017
Q1 		$748K Buy
219,712
+208,330
+1,830% +$985K 0.04% 151
2016
Q4 		$59K Sell
11,382
-393
-3% -$6.8K ﹤0.01% 282
2016
Q3 		$297K Sell
11,775
-725
-6% -$18.3K 0.01% 256
2016
Q2 		$309K Sell
12,500
-12,365
-50% -$349K 0.02% 229
2016
Q1 		$720K Buy
+24,865
New +$675K 0.04% 187
2014
Q3 		– Sell
-56,000
Closed -$1.18M – 322
2014
Q2 		$1.52M Sell
56,000
-30,005
-35% -$741K 0.07% 121
2014
Q1 		$2.31M Sell
86,005
-128,365
-60% -$3.26M 0.13% 100
2013
Q4 		$5.26M Sell
214,370
-4,955
-2% -$128K 0.34% 48
2013
Q3 		$7.05M Sell
219,325
-19,098
-8% -$592K 0.46% 45
2013
Q2 		$7.07M Buy
+238,423
New +$8.9M 0.47% 49

Other funds holding ANTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sabby Management's ANTH Position: Q4 2017 in Review

Sabby Management sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2017, closing a stake of 52,046 shares — an estimated $89.6K sold.

Sabby Management first reported a position in ANTH in Q2 2013 and held it in 12 quarters. The position peaked at $7.07M in Q2 2013. 37 funds tracked by Wall St. Rank hold ANTH as of Q4 2017.

  • Sabby Management reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Sabby Management sold 52,046 Anthera Pharmaceuticals, Inc. shares in Q4 2017, an estimated $89.6K.
  • Sabby Management first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 12 quarters.
  • Sabby Management's Anthera Pharmaceuticals, Inc. position peaked at $7.07M in Q2 2013.
  • 37 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2017.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.